SynthesisFrontiers in oncology2025
Prognostic role of fibrinogen-to-albumin ratio in patients with gynecological cancers: a meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Fibrinogen-to-Albumin Ratio in Endometriosis: A Step Toward Personalized Non-Invasive Diagnostics.Journal of personalized medicine · 2026Article
- Diagnostic Power of the Fibrinogen-to-Albumin Ratio for Estimating Malignancy in Patients with Adnexal Masses: A Methodological Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibrinogen-to-albumin ratio (FAR) has been widely studied for its prognostic value in gynecological cancers, but the results remain inconsistent. Therefore, this study aimed to evaluate the precise prognostic significance of FAR in gynecological cancers. Methods: A comprehensive literature search was conducted in PubMed, Web of Science, Embase, the Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases up to 12 May 2025. The prognostic value of FAR for overall survival (OS) and progression-free survival (PFS) in gynecological cancers was examined using pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results: A total of 10 articles comprising 1,902 patients were included in this meta-analysis. Pooled results indicated that elevated FAR was significantly associated with poor OS (HR = 2.75, 95% CI: 2.26-3.36, Conclusion: This meta-analysis showed that a high FAR is significantly associated with worse OS and PFS in patients with gynecological cancers. FAR may serve as a promising prognostic biomarker in clinical practice. Systematic review registration: https://inplasy.com/inplasy-2025-5-0036/, identifier INPLASY202550036.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.